Abstract: Formulations of azole antifungals such as itraconazole and particularly formulations, co-formulations and compositions of itraconazole with one or more oligomeric and/or polymeric excipients are disclosed. Methods for preparation of the formulations, co-formulations and compositions include co-precipitating the two materials from a common solvent or solvent mixture using a compressed (typically supercritical or near-critical) fluid anti-solvent as in the GAS (Gas Anti-Solvent) precipitation method. The formulations, co-formulations, compositions, methods of making and methods of delivering, are useful as pharmaceutical compositions and in medical treatment by virtue of their at least parity, preferably improved or enhanced solubility or dissolution characteristics, resulting in at least parity, preferably improved or enhanced bioavailability and/or pharmacokinetics.

Abstract: A polyalkylene glycol (PAG)—preferably a polyethylene glycol—or a derivative or conjugate thereof, in particulate form, having a residual solvent content of 200 ppm or less and a volume mean particle diameter of 25 &mgr;m or less. Also methods for forming particulate products containing PAGs or derivatives or conjugates thereof, in particular by carrying out a GAS process—preferably a Nektar™ SCF process—on a solution or suspension of a target substance but using as the anti-solvent fluid a compressed fluid which at the point of its contact with the solution or suspension is at a temperature of 25° C. or below.